PHARM.AS stock EUR 1.49 pre-market, 16.87M volume 21 Jan 2026: Forecasts ahead
PHARM.AS stock opened pre-market at EUR 1.49 on 21 Jan 2026 and trades with heavy volume of 16,871,113.00 shares. Activity is above the 50-day average volume and keeps the equity among Europe’s most active names on EURONEXT. Investors are watching upcoming catalysts, including an earnings release scheduled for 12 Mar 2026, and recent trading suggests short-covering and headline-driven flows.
PHARM.AS stock pre-market snapshot
PHARM.AS stock trades on EURONEXT in Europe at EUR 1.49 with a one-day change of -1.97%. The session high is EUR 1.51 and the low is EUR 1.46. Volume stands at 16,871,113.00, versus an average of 16,014,745.00, giving a relative volume of 1.05. The market cap is EUR 1,039,458,853.00 and shares outstanding are 696,688,239.00.
Why the stock is most active pre-market
Trading activity reflects a mix of news flow and positioning. Recent headlines show elevated short interest and analyst commentary that increase intraday liquidity. The upcoming earnings date on 12 Mar 2026 is a near-term catalyst for PHARM.AS stock. Institutional flows and retail attention to the biotechnology sector also lift trading volumes for mid-cap drug developers.
PHARM.AS stock fundamentals and valuation
Pharming Group N.V. reports EPS of -0.01 and a reported PE of -149.20, reflecting a loss-making or volatile earnings base. Key valuation multiples include PB 4.42, P/S 3.36, and EV/Sales 3.36. Liquidity metrics show a current ratio of 3.16 and debt/equity of 0.49, indicating a conservative balance sheet. Revenue per share is 0.54 and free cash flow per share is 0.08, suggesting cash generation despite low net margins.
Technical picture and sector context for PHARM.AS stock
Momentum indicators show an RSI of 71.76, signaling short-term overbought conditions. The 50-day average price is EUR 1.45 and the 200-day average is EUR 1.13, supporting a bullish medium-term trend. Healthcare peers show an average PE near 34.60, so Pharming’s negative PE positions it differently within the sector. Traders should watch the Bollinger upper band at EUR 1.55 for a breakout or pullback signal.
Meyka grading and technical snapshot for PHARM.AS stock
Meyka AI rates PHARM.AS with a score out of 100. Meyka AI rates PHARM.AS with a score out of 100: 64.44 (Grade B) — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show MACD histogram positive and an ADX of 19.35, implying limited trend strength. We note short-term overbought oscillators and above-average volume.
Risks and catalysts shaping PHARM.AS stock action
Primary catalysts include the Ruconest commercial trajectory and pipeline readouts for rhC1INH and leniolisib. Collaborations with Novartis and Orchard Therapeutics add development optionality. Key risks are clinical setbacks, pricing pressure, and biotech sector rotation. Volatility metrics and high days-of-inventory suggest operational complexity that can amplify price moves in either direction.
Final Thoughts
Key takeaways for PHARM.AS stock: current price sits at EUR 1.49 with strong pre-market volume of 16,871,113.00. Fundamentals show solid liquidity metrics and cash flow per share of 0.08, but negative EPS keeps traditional valuation measures stretched. Meyka AI’s forecast model projects a yearly price of EUR 1.93, implying an upside of 29.40% versus the current price. That forecast is model-based and not a guarantee. Traders focused on the most active list should weigh upcoming earnings on 12 Mar 2026, biotech pipeline catalysts, and short-interest dynamics. Our view: monitor volume and RSI for near-term reversals, and use position sizing to manage the biotech-specific risk profile. Meyka AI, an AI-powered market analysis platform, provides these data-driven signals to help frame opportunity and risk.
FAQs
What drives PHARM.AS stock volume today?
PHARM.AS stock sees high volume from increased short interest, headline flows, and positioning ahead of the 12 Mar 2026 earnings date. Retail and institutional trading in biotech names also lifts liquidity.
What is Meyka’s rating for PHARM.AS stock?
Meyka AI rates PHARM.AS with a score out of 100: 64.44 (Grade B) with a HOLD suggestion. The grade factors in benchmarks, sector and financial metrics and analyst consensus.
What price target does Meyka give for PHARM.AS stock?
Meyka AI’s forecast model projects a one-year price of EUR 1.93 for PHARM.AS stock, implying about 29.40% upside from EUR 1.49. Forecasts are model projections and not guarantees.
How should investors manage risk in PHARM.AS stock?
Manage risk with small position sizes, stop limits, and attention to pipeline updates and the 12 Mar 2026 earnings report. PHARM.AS stock is volatile; use portfolio diversification and monitor volume signals.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
